ProQR Therapeutics NV reports results for the quarter ended in December - Earnings Summary

ProQR Therapeutics NV

29/03/2023 22:22

* ProQR Therapeutics NV  PRQR.OQ  reported a quarterly
adjusted
loss of 16 cents​​ per share for the quarter ended in December.
The mean expectation of seven analysts for the quarter was for a
loss of 16 cents per share.
    * Revenue rose 85.1% to €822.00 thousand from a year ago;
analysts
expected €956.32 thousand. 
    * ProQR Therapeutics NV's reported EPS for the quarter was a
loss
of 16 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * ProQR Therapeutics NV shares had fallen by 3.2% this
quarter.
    * The company reported a quarterly loss of €11.39 million.
    * Wall Street's median 12-month price target for ProQR
Therapeutics NV is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 29 at 09:22 p.m. UTC. ​All figures in euros unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.16          -0.16          Met
 Sep. 30 2022      -0.21          -0.34          Missed
 Jun. 30 2022      -0.22          -0.21          Beat
 Mar. 31 2022      -0.24          -0.20          Beat